Vioguard Secures $5MM Series A Financing Round Led by Imagen Capital Partners

Wednesday, January 25, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Financing will be used to accelerate sales, marketing and execution of product roadmap

BOTHELL, Wash., Jan. 25, 2017 /PRNewswire/ -- Vioguard Inc., an industry leader in UV-C technology solutions, today announced

that it has raised a $5 million Series A round of financing from Imagen Capital Partners. This investment brings Vioguard's total funding since launching its ultraviolet disinfection solutions to $11 million and will be used to expand its sales and marketing efforts, as well as, broaden and accelerate product development initiatives. With this investment, Imagen Capital Partners will designate two persons to join the Vioguard board of directors.

Vioguard, an industry leader in UV-C technology solutions designed to enhance the effectiveness of infection control strategies, believes this investment will further enable it to develop its products and execute on its business strategy. Vioguard's patented flagship product is a self-sanitizing automated keyboard and mouse system that uses high-powered germicidal ultraviolet light, known as UV-C. This system, which has been cleared by the U.S. Food and Drug Administration, effectively kills 99.99 percent of all bacteria, viruses, fungi, and drug-resistant pathogens that have been proven to be responsible for millions of Hospital-Acquired Infections (HAIs) worldwide.

"I believe the investment by Imagen will help Vioguard advance our leadership position within the ultraviolet disinfection arena," said Laurance Ranta, President and Chief Executive Officer of Vioguard. "We are pleased to welcome Imagen Capital Partners as a shareholder and look forward to an exciting and prosperous future with them." 

Commenting on the transaction, Chris Barrow, managing director at Imagen Capital Partners, stated, "We are excited about Vioguard's technology platform and its leadership team as they continue their efforts to bring pioneering UV-C solutions to the worldwide marketplace."

Vioguard currently holds multiple patents in the UV space for sanitizing surfaces, such as computer keyboards, touchscreens, telephones, escalator handrails, writing implements, as well as various other surfaces and input devices. Additional product introductions are expected to include an escalator handrail sanitizer and a pen sterilizing device, both projected to be released across 2017.

About Vioguard

Established in 2008 by technology professionals interested in combating Hospital-Acquired Infections (HAIs), Vioguard is passionately committed to developing products and solutions designed to enhance the effectiveness of infection control strategies without compromising productivity or accuracy. Its mission, by working with industry professionals, is to save lives, reduce sickness and stop the spread of deadly pathogens by developing products for infection prevention.  To learn more, go to www.vioguard.com

About Imagen Capital Partners

Imagen Capital Partners, based in Seattle and Park City, Utah, is a venture capital fund focused on investing in early-stage technology companies and businesses. The firm seeks to invest predominantly in seed and Series A rounds across the technology spectrum. Its team of experienced entrepreneurs has a significant history and track record in building entrepreneurial companies and seeks to leverage this broad industry knowledge to work with entrepreneurs who seek to innovate, challenge and fundamentally change the dynamics of new and existing markets.   

Release Summary Bothell, Wash.-based Vioguard has announced that it has raised a $5 million round of financing from Imagen Capital Partners.

Sharing Facebook:  Vioguard Corp and Twitter: @Vioguard

Contact: Laurance Ranta 425-318-7900 [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vioguard-secures-5mm-series-a-financing-round-led-by-imagen-capital-partners-300396432.html

SOURCE Vioguard Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store